Alphabet Earnings: GOOGL + Note on SPY Options
Google reported earnings on July 25, and investor response was positive. We liked what we saw as well. Interestingly, the price of Alphabet stock has underperformed other mega-cap tech stocks…
Google reported earnings on July 25, and investor response was positive. We liked what we saw as well. Interestingly, the price of Alphabet stock has underperformed other mega-cap tech stocks…
Investors have ignored the mining companies for more than a decade as people wanted to focus on the GoGo tech stocks. People did not care much about value stocks, which…
On 8-May-2023, we discussed a buy-write, aka covered call strategy applied to Exxon Mobile stock. This article is for paid members - please login or subscribe for access.
Discover Financial Services (DFS) reported Q2 2023 earnings last week, and traders were unimpressed. Traders took the stock down $19.40 a share or 15.9%. Our question is, "Were the results…
Few industries were hit harder than the cruise industry during the C-19 lockdown. The reason for this is clear. This article is for paid members - please login or subscribe…
Finding an un devalued stock in the tech space is becoming more challenging. Investors have bid up the price of software and device companies assuming they will perform to perfection.…
One of the biggest, if not the biggest winner we have ever discussed here at theOptionsEdge.Com, is Microstrategy, the business intelligence software company and largest publicly traded bitcoin holder. This…
Estee Lauder is one of the big success stories in the Beauty Industry. It has a highly recognized brand name and has historically captured a price premium for the high-quality…
T-Mobile stock was the big winner in the wireless wars between ATT, Verison & T-Mobile. Will it continue to be a winner, or is growth through acquisition and market-share accretion…
Companies in the biopharmaceutical are challenging to get your arms around. The development of pharmaceutical treatments is highly technical and requires scientific insight. Further, developing these therapies is expensive and…